Literature DB >> 3032447

Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.

L Lombardi, E W Newcomb, R Dalla-Favera.   

Abstract

To study the pathogenesis of Burkitt lymphoma, we introduced activated c-myc genes into human EBV-infected lymphoblastoid cells derived from in vitro infection of normal cord blood or directly from infected peripheral blood from AIDS patients. In both cell types the constitutive expression of exogenous c-myc caused negative regulation of endogenous c-myc expression, changes in growth properties typical of transformed cells, and acquisition of tumorigenicity in immunodeficient mice. In all myc-transfected populations the degree of malignancy directly correlated with the level of c-myc mRNA. EBV infection and c-myc activation are thus sufficient for the tumorigenic conversion of human B cells in vitro, strongly supporting the hypothesis that these same two pathogenetic steps may be involved in the in vivo development of Burkitt lymphoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032447     DOI: 10.1016/0092-8674(87)90556-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  51 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene.

Authors:  B C Lewis; H Shim; Q Li; C S Wu; L A Lee; A Maity; C V Dang
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Efficient retroviral-mediated gene transfer into human B lymphoblastoid cells expressing mouse ecotropic viral receptor.

Authors:  B W Baker; D Boettiger; E Spooncer; J D Norton
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

4.  Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression.

Authors:  Brygida Bisikirska; Mukesh Bansal; Yao Shen; Julie Teruya-Feldstein; Raju Chaganti; Andrea Califano
Journal:  Cancer Res       Date:  2015-11-20       Impact factor: 12.701

Review 5.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

6.  NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.

Authors:  L Ji; M Arcinas; L M Boxer
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells.

Authors:  B W Cherney; K Bhatia; G Tosato
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Structural and functional characterization of the promoter regions of the NFKB2 gene.

Authors:  L Lombardi; P Ciana; C Cappellini; D Trecca; L Guerrini; A Migliazza; A T Maiolo; A Neri
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

9.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

Authors:  A Polack; K Hörtnagel; A Pajic; B Christoph; B Baier; M Falk; J Mautner; C Geltinger; G W Bornkamm; B Kempkes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

10.  AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus.

Authors:  Joel R Wilmore; Amolo S Asito; Chungwen Wei; Erwan Piriou; P Odada Sumba; Iñaki Sanz; Rosemary Rochford
Journal:  Int J Cancer       Date:  2014-08-19       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.